TrialDrugs & aging2021

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.

Susann Varano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.